Pharvaris (PHVS) Other Non-Current Liabilities (2023 - 2024)
Pharvaris (PHVS) posted Other Non-Current Liabilities of $4.0 million for Q4 2024, up 458.4% on a QoQ basis from $723555.6 in Q4 2023, and up 458.4% year-over-year from $723555.6 in Q1 2024.
Pharvaris (PHVS) Other Non-Current Liabilities (2023 - 2024) Analysis & Trends
Pharvaris' Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $4.0 million for Q4 2024.
- Quarterly Other Non-Current Liabilities rose 458.4% year-over-year to $4.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $4.0 million (up 458.4% YoY) and the FY2024 annual result came in at $4.1 million, up 462.56% from the prior year.
- Other Non-Current Liabilities was $4.0 million for Q4 2024 at Pharvaris, up from $723555.6 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $4.0 million in Q4 2024 and bottomed at $723555.6 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Pharvaris | 2.17 Bn | 1.88 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 4.04 Mn |
| Dec 31, 2023 | 723,555.60 |